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See Article, pages 374–380Statins are given to 10–20% of adults in developed countries. Stat-
ins increase alanine aminotransferase (ALT) concentrations in
10% of patients without liver disease, and this increase can
exceed more than three times the upper limit of normal in 1%
of such patients. In contrast, we will note that this ALT escalation
does not appear to occur when statins are initiated in patients
with fatty liver or hepatitis C.
In the ﬁeld of drug-induced liver disease, attempts are made
to distinguish between medicines that cause hepatotoxic reac-
tions and idiosyncratic reactions. The principal differences are
that hepatotoxic reactions are dose dependent and predictable
(e.g., acetaminophen); while idiosyncratic reactions are not dose
dependent or predictable (e.g., penicillin). Do statins cause liver
injury? This author has asserted with voluminous supporting
data that statins are not hepatotoxic [1].
Do statins cause rare idiosyncratic drug reactions? Probably.
In this issue, Bjornsson et al. present an epidemiological survey
of a monitoring system using RUCAM methodology to discover
drug toxicity [2].
The strengths of their work are the authors’ experience, the
22 years of observation, and that the database is limited to a sin-
gle country, Sweden. The report is fortiﬁed by their addition of
drug rechallenge cases, though drug rechallenge is not the gold
standard it was once thought. Positive rechallenge cases have
sometimes been discovered to accidentally take the identical
drug on a subsequent date without a problem; conversely, nega-
tive rechallenge cases sometimes experience a similar idiosyn-
cratic reaction later on the same drug. The problem lies partly
in cross reactivity of chemical moieties. The sensitivity and spec-
iﬁcity of a drug rechallenge to determine the cause of an idiosyn-
cratic reaction is poorly understood [3].
The weakness of the study is the reliance upon the Roussel
Uclaf Causality Assessment Method (RUCAM). RUCAM is a scor-
ing method that attempts to quantify clinical judgment. Amongst
a multitude of problems, the RUCAM suffers from a high degree
of interobserver variability [4,5]. Moreover, it is prejudicial
against statins by begging the question. That is, RUCAM scoring
assigns two points for a drug-induced liver reaction if the product
label contains a liver injury notation. As I have noted elsewhere,
the product labels of statins are terribly outdated with liverJournal of Hepatology 20
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when one looks even at the rechallenge cases by Bjornsson
et al. (Table 1, column 4) and then subtracts 2 points from each
case because of circular reasoning, the interpretation of ﬁnal
scoring might move from ‘‘highly probable’’ to only ‘‘probable’’.
While efforts are being made to improve the accuracy of
RUCAM [5], the positive predictive value of a method which is
89% speciﬁc for a condition that occurs once in every 100,000
cases is far less than 1%. Thus, there is still legitimate doubt that
these cases truly represent statin related idiosyncrasies. In
defense of the authors, this was the best method available for this
inquiry; but it serves to point out the immaturity of the ﬁeld of
drug-induced liver disease. What is needed in the ﬁeld is the
application of solid science using drug protein adducts and
pharmacogenomics.
The determined frequency of liver injury, 1/100,000 users, may
be an overestimate since others have suggested a prevalence of 1/
1,000,000 [6]. Moreover, an internal comparison suggesting this
article overestimates the frequency of idiosyncratic liver reactions
to statins is that this is the ﬁrst report the author is aware of for
which this effect on the liver occurredmore often than severemus-
cle injury. Usually, myopathy is a more common side-effect than
idiosyncratic liver damage. The authors recognize this inverted
aspect of their ﬁndings, but have no ready explanation.
Whether or not statins cause acute liver failure has still not
been determined. It has been difﬁcult to ascertain the overall
incidence of acute liver failure (ALF) in the United States. This
reviewer has no information for the rate of idiopathic ALF in
Scandinavia. Tolman estimated the idiopathic ALF rate in the
USA to be from 0.5 to 1.0 cases per million, and the incidence
of possible statin-induced ALF to be 0.2 cases per million [7].
The rate in the current study appears to be around 1 per million
and thus one cannot tell whether statins are involved in ALF due
to background noise.
Regardless, this report of idiosyncratic drug reactions needs to
be put into perspective.
In large 5–10 year trials, statins prevent about 33% of major
cardiovascular events when compared to placebo. In other words,
the number needed to treat (NNT) is 3. If statins cause serious
liver disease, it is on the order of 1/100,000 to 1/1000,000. The
number needed to harm (NNH) is about 1 million. Estimates of
patients who fail to receive statins out of fear of hepatotoxicity
range from 10% to 30% [1]. Thus, the anxiety over this possible
drug reaction, which if it exists is extremely rare, causes12 vol. 56 j 305–307
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thousands of patients to needlessly suffer fatal cardiovascular
events. My advocacy stems from the frustration of liver trans-
plant candidates who are denied listing because of advanced cor-
onary artery disease; patients who may have been eligible for
listing had they been put on a statin in a timely manner. The lit-
erature shows that from 7% to 29% of liver transplantation candi-
dates are denied listing due to coronary disease [8].
What about prescribing statins for patients with liver disease
and cardiac risk factors?
Dr. Zimmerman, the late doyen of drug-induced liver injury,
reminded us: ‘‘A stubborn misconception regarding susceptibility
to hepatic injury has been the view that patients with preexisting
liver disease are more likely than others to experience hepatic
injury on exposure to drugs that cause liver damage’’ [9].
Hepatologists in Europe and the United States have a bias
against using statins in patients with liver disease who have
hypercholesterolemia [1]. A more recent trial in 403 patients
with hepatitis C reported statin use in only 12 patients [10].
Fatty liver is by far the most common liver disease encoun-
tered. We are doing a distinct disservice by not prescribing stat-
ins for this group. Why? The prospective Cremona study from
Italy, a 15 year follow-up of patients with fatty liver, has shown
us that these patients are seven times more likely to die of car-
diac disease than liver disease [11].
Athyros et al. reported data from a Greek randomized trial of
the efﬁcacy and safety of statins in patients with baseline
increases of ALT that were less than three times the upper limit
of normal. All of these patients were thought to have fatty liver.
In patients with fatty liver, serious increases of ALT occurred no
more often than in a similar group who were not given statins.
Moreover, ALT improved or normalized in patients who were
given statins, whereas in the group not given statins, liver tests
continued to worsen. Most importantly, patients who started
the trial with elevated liver tests derived the greatest cardiovas-
cular beneﬁt of any group – a favorable effect (50%), which was
substantially greater for these patients than for patients who
started statins with in-range liver tests! The uniform improve-
ment in liver tests for fatty liver patients noted by Athyros
et al. matches our observations in patients with hepatitis C who
are given statins [12,13].
Space limits a discussion of all liver diseases. Extensive data
exist as to cardiac mortality in HCV and HBV. Hepatitis C confers
a signiﬁcant increase in cardiovascular disease mortality both in
the USA and United Kingdom [14,15]. On the other hand, patients
who are positive for hepatitis B surface antigen have neither an
increased or decreased risk of cardiovascular disease [14,15].
We have shown no elevation of ALTs in more than 100 HCV
patients prospectively given statins for periods of up to 72 weeks
(unpublished and [16]). Others have had the same experience in
over 200 HCV patients [17,18]. Moreover, we and others have
documented uniform improvements in ALT values in HCV
patients given statins [19,20].
We have preliminary data in 13 HBV patients. HBV patients
neither increase nor decrease their ALT values when given statins
prospectively (unpublished). Surely, with HBV infection being the
most common chronic infectious disease worldwide (400 million
carriers), it is quite likely that millions of patients have been
given statins accidently over the past 23 years without reports
of special hepatotoxicity.
However, in contrast to fatty liver disease, the author is una-
ware of any long-term cardiovascular prevention trials with stat-306 Journal of Hepatology 201ins in patients with HBV or HCV; such trials have usually
excluded patients with liver disease. Nonetheless, there is no rea-
son to suspect that statins would have any diminished efﬁcacy.
Does monitoring with ALT tests help to predict this rare
injury? No.
The authors end their current report with wise counsel:
‘‘Responsible physicians should measure liver tests in patients
taking statins with newly developed symptoms such as nausea,
severe lethargy and abdominal pain.’’ I agree. This is the same
approach shown useful in detecting severe cases of INH toxicity
in early stages. ALT monitoring for statins does more harm than
good by discovering the irrelevant ﬁnding of 1 in 10 patients
who will elevate their ALT level; elevations that will return to
normal even if the same statin is continued.
Billions of dollars are spent on useless monitoring of ALT
enzymes during statin therapy that could be used for much better
health care purposes [1]. But the worst side effect of this mislead-
ing monitoring is the terrible cost in human life by frightening
physicians and patients away from the cardiac prevention poten-
tial of statin use.
A problem of interpretation could arise when a patient expe-
riences a ﬂare of their intrinsic liver disease. If dramatic eleva-
tions of ALT take place (i.e., >3X baseline or >5X ULN), my
advice would be to watch the trend and consider holding all
drugs possible while the liver tests subside. If from the myriad
possibilities, the clinician determines the statin may be the cause,
the statin can be switched. In the current study by Bjornsson
et al., when patients were switched, the subsequent statin did
not elicit an idiosyncratic reaction.
In summary, the elevation of ALT values that commonly occur
at the start of statin therapy have no meaning in regard to hepa-
totoxicity. On the other hand, Bjornsson et al. present data that
show drug idiosyncrasy due to statins probably exists, but is rare.
ALT monitoring does not help to discover an idiosyncratic reac-
tion. Patients started on statins should be counseled about possi-
ble symptoms of drug-induced hepatitis but told how rare this is.
Giving a statin to those patients with liver disease and cardiac
risk factors may increase their lifespan more than any other ther-
apy we offer. Writing this prescription would produce greater
longevity, with far less risk, than liver transplantation for patients
with fatty liver or peginterferon based triple therapy for hepatitis
C. For liver patients with cardiac risk factors, the pen is mightier
than the knife or needle!Conﬂict of interest
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